Hepatitis - Pipeline Review, H2 2012


#135265

356pages

Global Markets Direct

$ 2500

In Stock


Hepatitis Pipeline Review, H2 2012

Global Markets Directs, 'Hepatitis Pipeline Review, H2 2012', provides an overview of the Hepatitis therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. 'Hepatitis Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hepatitis.
  • A review of the Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hepatitis pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hepatitis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hepatitis pipeline depth and focus of Hepatitis therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hepatitis Therapeutic Products under Development, Key Players in Hepatitis Therapeutics, Hepatitis Pipeline Overview, Hepatitis Pipeline, Hepatitis Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Hepatitis Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Hepatitis 16
Hepatitis Therapeutics under Development by Companies 18
Hepatitis Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 35
Comparative Analysis 35
Mid Clinical Stage Products 36
Comparative Analysis 36
Early Clinical Stage Products 37
Comparative Analysis 37
Discovery and Pre-Clinical Stage Products 38
Comparative Analysis 38
Hepatitis Therapeutics Products under Development by Companies 39
Hepatitis Therapeutics Products under Investigation by Universities/Institutes 60
Companies Involved in Hepatitis Therapeutics Development 66
Bristol-Myers Squibb Company 66
Boehringer Ingelheim GmbH 67
F. Hoffmann-La Roche Ltd. 68
Abbott Laboratories 69
United Therapeutics Corporation 70
Medgenics Inc. 71
Valeant Pharmaceuticals International 72
GlaxoSmithKline plc 73
Tekmira Pharmaceuticals Corp. 74
Inovio Biomedical Corporation 75
Idenix Pharmaceuticals, Inc. 76
Gilead Sciences, Inc. 77
Merck & Co., Inc. 78
Lentigen Corporation 79
BioLineRx, Ltd. 80
Celltrion, Inc. 81
Ambrilia Biopharma Inc. 82
Biotron Limited 83
Novartis AG 84
Achillion Pharmaceuticals, Inc. 85
Human Genome Sciences, Inc. 86
InterMune, Inc. 87
Ono Pharmaceutical Co., Ltd. 88
Pfizer Inc. 89
SuperGen, Inc. 90
Toyama Chemical Co. Ltd 91
Vertex Pharmaceuticals Incorporated 92
Genmab A/S 93
Santaris Pharma A/S 94
Tacere Therapeutics, Inc. 95
Aduro BioTech 96
Alfacell Corporation 97
CEL-SCI Corporation 98
Crucell N.V. 99
Celgene Corporation 100
Zosano Pharma, Inc. 101
4SC AG 102
EpiCept Corporation 103
Hemispherx Biopharma, Inc. 104
Agenix Limited 105
Immtech Pharmaceuticals, Inc. 106
Can-Fite BioPharma Ltd. 107
Arrowhead Research Corporation 108
Ligand Pharmaceuticals Incorporated 109
Medivir AB 110
Benitec Ltd. 111
BioDiem Ltd 112
Biota Holdings Limited 113
NanoViricides, Inc. 114
Novelos Therapeutics, Inc. 115
Patrys Limited 116
Peregrine Pharmaceuticals, Inc. 117
CytoGenix, Inc. 118
Amarillo Biosciences, Inc. 119
BioCryst Pharmaceuticals, Inc. 120
Flamel Technologies S.A. 121
Dynavax Technologies Corporation 122
Transgene SA 123
Lipoxen PLC 124
Bukwang Pharmaceutical Co., Ltd. 125
Miraca Holdings Inc. 126
Green Cross Corporation 127
Hanall Pharmaceutical Co., Ltd. 128
MOLOGEN AG 129
LG Life Sciences, Ltd 130
Samaritan Pharmaceuticals, Inc. 131
LTT Bio-Pharma Co., Ltd. 132
Uni-Bio Science Group Ltd. 133
Panacea Biotec Limited 134
Summit Corporation plc 135
Phynova Group Ltd 136
Tripep AB 137
Digna Biotech, S.L. 138
Debiopharm Group 139
Immune Network Research Ltd. 140
StemCells, Inc. 141
Colby Pharmaceutical Company 142
Maywufa Company Limited 143
SCYNEXIS, Inc. 144
Nutri Pharma ASA 145
Mucosis B.V. 146
Biolex Therapeutics, Inc. 147
Cytheris SA 148
Altor BioScience Corporation 149
Eiger BioPharmaceuticals, Inc. 150
AiCuris GmbH & Co. KG 151
Okairos 152
GeneScience Pharmaceuticals Co., Ltd. 153
PTC Therapeutics, Inc. 154
Conatus Pharmaceuticals Inc. 155
Presidio Pharmaceuticals, Inc. 156
Romark Laboratories, L.C. 157
Chimerix, Inc. 158
Phage Biotechnology Corporation 159
Intarcia Therapeutics, Inc. 160
REPLICor Inc. 161
Biotica Technology Ltd 162
Sinovac Biotech Ltd. 163
VLST Corporation, Inc. 164
Virobay Inc. 165
Concert Pharmaceuticals, Inc. 166
Implicit Bioscience Limited 167
NanoBio Corporation 168
Bolder Biotechnology, Inc. 169
ImmunoVaccine Technologies Inc. 170
Oncolys BioPharma Inc. 171
Globeimmune, Inc. 172
Immunocore Limited. 173
Enanta Pharmaceuticals, Inc. 174
Canopus BioPharma Incorporated 175
PepTcell Limited 176
Arisyn Therapeutics Inc. 177
TVAX Biomedical, LLC 178
Jenken Biosciences, Inc 179
Epiphany Biosciences, Inc. 180
GenPhar, Inc. 181
Asklepios BioPharmaceutical, Inc. 182
Beckpharma Limited 183
CureTech Ltd. 184
TaiGen Biotechnology Co., Ltd. 185
IRX Therapeutics, Inc. 186
PharmaEssentia Corporation 187
NasVax Ltd. 188
Regulus Therapeutics Inc. 189
Gaia BioPharma Limited 190
Ascendis Pharma A/S 191
ViiV Healthcare 192
Biopartners Holdings AG 193
Therapure Biopharma Inc. 194
Vaxine Pty Ltd 195
VectorLogics, Inc. 196
iTherX Pharmaceuticals Inc. 197
VLP Biotech, Inc. 198
ImQuest Life Sciences 199
Hepatitis Therapeutics Assessment 200
Assessment by Monotherapy Products 200
Assessment by Combination Products 201
Assessment by Route of Administration 202
Assessment by Molecule Type 204
Drug Profiles 207
Vaniprevir - Drug Profile 207
BI 201335 - Drug Profile 208
Viread - Drug Profile 210
Alferon N Injection - Drug Profile 212
Heplisav - Drug Profile 213
Clevudine - Drug Profile 215
simeprevir - Drug Profile 217
Asunaprevir - Drug Profile 219
Consensus Interferon + Ribavirin - Drug Profile 221
Infliximab + Pegintron + Ribavirin - Drug Profile 223
Lipiocis - Drug Profile 225
AdoMet + Betaine + Pegylated Interferon Alpha 2b + Ribavirin - Drug Profile 226
TMC435 + PEGIFNalpha-2A + Ribavirin - Drug Profile 228
Daclatasvir - Drug Profile 230
BMS-790052 + BMS-650032 - Drug Profile 232
BMS-790052 + BMS-650032 + Pegylated-Interferon Alpha + Ribavirin - Drug Profile 233
Pegasys + Tenofovir - Drug Profile 235
Victrelis + Peginterferon Alfa-2b + Ribavirin - Drug Profile 237
Boceprevir + Peginterferon Alfa-2b + Ribavirin + Erythropoietin - Drug Profile 239
Pegylated Interferon Alfa-2a + Adefovir - Drug Profile 241
Entecavir + Branched-Chain Amino Acids - Drug Profile 242
Peginterferon Alfa-2a + Ribavirin - Drug Profile 243
Peginterferon Alpha-2a + Ribavirin + Meloxicam - Drug Profile 244
MK7009 + Pegintron + Rebetol - Drug Profile 246
Prednisolone + N Acetyl Cysteine - Drug Profile 249
Interferon Alpha-2b + Ribavirin + Interferon-Gamma - Drug Profile 250
Lopinavir + Ritonavir + Nucleoside Reverse Transcriptase Inhibitors + PEG-IFNa 2a + Ribavirin - Drug Profile 252
Entecavir - Drug Profile 254
Pegaferon + Ribavirin - Drug Profile 255
Intron A + Ribavirin - Drug Profile 256
Nitazoxanide - Drug Profile 257
Pioglitazone + Pegylated Interferon + Ribavirin - Drug Profile 259
DTP-HepB-Polio-Hib - Drug Profile 261
DTP-HepB/Hib Vaccine - Drug Profile 262
BI 201335 + Pegylated Interferon Alpha + Ribavirin - Drug Profile 263
Peginterferon Alfa-2b + Ribavirin + Vitamin D - Drug Profile 264
BMS-914143 + BMS-790052 + Ribavirin - Drug Profile 265
GS-7977 - Drug Profile 267
V419 + Prevnar 13 + RotaTeq - Drug Profile 269
BMS-790052 + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile 271
Lamivudine + Adefovir - Drug Profile 273
Telbivudine + Adefovir - Drug Profile 274
Nitazoxanide + Pegylated Interferon Alfa 2a + Ribavirin - Drug Profile 275
Silymarin - Drug Profile 277
Hepavax-Gene - Drug Profile 278
Hexaxim - Drug Profile 279
PSI-7977 + Ribavirin - Drug Profile 280
Ribavirin + Peginterferon Alpha-2a - Drug Profile 282
Peginterferon Alfa 2a + Ribavirin - Drug Profile 284
Entecavir + Pegasys - Drug Profile 285
Hepabulin IV - Drug Profile 286
Hepatitis Therapeutics Drug Profile Updates 287
Hepatitis Therapeutics Discontinued Products 315
Hepatitis Therapeutics - Dormant Products 323
Hepatitis Product Development Milestones 344
Featured News & Press Releases 344

Appendix 352
Methodology 352
Coverage 352
Secondary Research 352
Primary Research 352
Expert Panel Validation 352
Contact Us 353
Disclaimer 353

Number of Products Under Development for Hepatitis, H2 2012 19
Products under Development for Hepatitis Comparative Analysis, H2 2012 20
Number of Products under Development by Companies, H2 2012 22
Number of Products under Development by Companies, H2 2012 (Contd..1) 23
Number of Products under Development by Companies, H2 2012 (Contd..2) 24
Number of Products under Development by Companies, H2 2012 (Contd..3) 25
Number of Products under Development by Companies, H2 2012 (Contd..4) 26
Number of Products under Development by Companies, H2 2012 (Contd..5) 27
Number of Products under Development by Companies, H2 2012 (Contd..6) 28
Number of Products under Development by Companies, H2 2012 (Contd..7) 29
Number of Products under Development by Companies, H2 2012 (Contd..8) 30
Number of Products under Development by Companies, H2 2012 (Contd..9) 31
Number of Products under Development by Companies, H2 2012 (Contd..10) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Development by Companies, H2 2012 (Contd..6) 48
Products under Development by Companies, H2 2012 (Contd..7) 49
Products under Development by Companies, H2 2012 (Contd..8) 50
Products under Development by Companies, H2 2012 (Contd..9) 51
Products under Development by Companies, H2 2012 (Contd..10) 52
Products under Development by Companies, H2 2012 (Contd..11) 53
Products under Development by Companies, H2 2012 (Contd..12) 54
Products under Development by Companies, H2 2012 (Contd..13) 55
Products under Development by Companies, H2 2012 (Contd..14) 56
Products under Development by Companies, H2 2012 (Contd..15) 57
Products under Development by Companies, H2 2012 (Contd..16) 58
Products under Development by Companies, H2 2012 (Contd..17) 59
Products under Development by Companies, H2 2012 (Contd..18) 60
Products under Development by Companies, H2 2012 (Contd..19) 61
Products under Development by Companies, H2 2012 (Contd..20) 62
Products under Investigation by Universities/Institutes, H2 2012 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 68
Bristol-Myers Squibb Company, H2 2012 69
Boehringer Ingelheim GmbH, H2 2012 70
F. Hoffmann-La Roche Ltd., H2 2012 71
Abbott Laboratories, H2 2012 72
United Therapeutics Corporation, H2 2012 73
Medgenics Inc., H2 2012 74
Valeant Pharmaceuticals International, H2 2012 75
GlaxoSmithKline plc, H2 2012 76
Tekmira Pharmaceuticals Corp., H2 2012 77
Inovio Biomedical Corporation, H2 2012 78
Idenix Pharmaceuticals, Inc., H2 2012 79
Gilead Sciences, Inc., H2 2012 80
Merck & Co., Inc., H2 2012 81
Lentigen Corporation, H2 2012 82
BioLineRx, Ltd., H2 2012 83
Celltrion, Inc., H2 2012 84
Ambrilia Biopharma Inc., H2 2012 85
Biotron Limited, H2 2012 86
Novartis AG, H2 2012 87
Achillion Pharmaceuticals, Inc., H2 2012 88
Human Genome Sciences, Inc., H2 2012 89
InterMune, Inc., H2 2012 90
Ono Pharmaceutical Co., Ltd., H2 2012 91
Pfizer Inc., H2 2012 92
SuperGen, Inc., H2 2012 93
Toyama Chemical Co. Ltd, H2 2012 94
Vertex Pharmaceuticals Incorporated, H2 2012 95
Genmab A/S, H2 2012 96
Santaris Pharma A/S, H2 2012 97
Tacere Therapeutics, Inc., H2 2012 98
Aduro BioTech, H2 2012 99
Alfacell Corporation, H2 2012 100
CEL-SCI Corporation, H2 2012 101
Crucell N.V., H2 2012 102
Celgene Corporation, H2 2012 103
Zosano Pharma, Inc., H2 2012 104
4SC AG, H2 2012 105
EpiCept Corporation, H2 2012 106
Hemispherx Biopharma, Inc., H2 2012 107
Agenix Limited, H2 2012 108
Immtech Pharmaceuticals, Inc., H2 2012 109
Can-Fite BioPharma Ltd., H2 2012 110
Arrowhead Research Corporation, H2 2012 111
Ligand Pharmaceuticals Incorporated, H2 2012 112
Medivir AB, H2 2012 113
Benitec Ltd., H2 2012 114
BioDiem Ltd, H2 2012 115
Biota Holdings Limited, H2 2012 116
NanoViricides, Inc., H2 2012 117
Novelos Therapeutics, Inc., H2 2012 118
Patrys Limited, H2 2012 119
Peregrine Pharmaceuticals, Inc., H2 2012 120
CytoGenix, Inc., H2 2012 121
Amarillo Biosciences, Inc., H2 2012 122
BioCryst Pharmaceuticals, Inc., H2 2012 123
Flamel Technologies S.A., H2 2012 124
Dynavax Technologies Corporation, H2 2012 125
Transgene SA, H2 2012 126
Lipoxen PLC, H2 2012 127
Bukwang Pharmaceutical Co., Ltd., H2 2012 128
Miraca Holdings Inc., H2 2012 129
Green Cross Corporation, H2 2012 130
Hanall Pharmaceutical Co., Ltd., H2 2012 131
MOLOGEN AG, H2 2012 132
LG Life Sciences, Ltd, H2 2012 133
Samaritan Pharmaceuticals, Inc., H2 2012 134
LTT Bio-Pharma Co., Ltd., H2 2012 135
Uni-Bio Science Group Ltd., H2 2012 136
Panacea Biotec Limited, H2 2012 137
Summit Corporation plc, H2 2012 138
Phynova Group Ltd, H2 2012 139
Tripep AB, H2 2012 140
Digna Biotech, S.L., H2 2012 141
Debiopharm Group, H2 2012 142
Immune Network Research Ltd., H2 2012 143
StemCells, Inc., H2 2012 144
Colby Pharmaceutical Company, H2 2012 145
Maywufa Company Limited, H2 2012 146
SCYNEXIS, Inc., H2 2012 147
Nutri Pharma ASA, H2 2012 148
Mucosis B.V., H2 2012 149
Biolex Therapeutics, Inc., H2 2012 150
Cytheris SA, H2 2012 151
Altor BioScience Corporation, H2 2012 152
Eiger BioPharmaceuticals, Inc., H2 2012 153
AiCuris GmbH & Co. KG, H2 2012 154
Okairos, H2 2012 155
GeneScience Pharmaceuticals Co., Ltd., H2 2012 156
PTC Therapeutics, Inc., H2 2012 157
Conatus Pharmaceuticals Inc., H2 2012 158
Presidio Pharmaceuticals, Inc., H2 2012 159
Romark Laboratories, L.C., H2 2012 160
Chimerix, Inc., H2 2012 161
Phage Biotechnology Corporation, H2 2012 162
Intarcia Therapeutics, Inc., H2 2012 163
REPLICor Inc., H2 2012 164
Biotica Technology Ltd, H2 2012 165
Sinovac Biotech Ltd., H2 2012 166
VLST Corporation, Inc., H2 2012 167
Virobay Inc., H2 2012 168
Concert Pharmaceuticals, Inc., H2 2012 169
Implicit Bioscience Limited, H2 2012 170
NanoBio Corporation, H2 2012 171
Bolder Biotechnology, Inc., H2 2012 172
ImmunoVaccine Technologies Inc., H2 2012 173
Oncolys BioPharma Inc., H2 2012 174
Globeimmune, Inc., H2 2012 175
Immunocore Limited., H2 2012 176
Enanta Pharmaceuticals, Inc., H2 2012 177
Canopus BioPharma Incorporated, H2 2012 178
PepTcell Limited, H2 2012 179
Arisyn Therapeutics Inc., H2 2012 180
TVAX Biomedical, LLC, H2 2012 181
Jenken Biosciences, Inc, H2 2012 182
Epiphany Biosciences, Inc., H2 2012 183
GenPhar, Inc., H2 2012 184
Asklepios BioPharmaceutical, Inc., H2 2012 185
Beckpharma Limited, H2 2012 186
CureTech Ltd., H2 2012 187
TaiGen Biotechnology Co., Ltd., H2 2012 188
IRX Therapeutics, Inc., H2 2012 189
PharmaEssentia Corporation, H2 2012 190
NasVax Ltd., H2 2012 191
Regulus Therapeutics Inc., H2 2012 192
Gaia BioPharma Limited, H2 2012 193
Ascendis Pharma A/S, H2 2012 194
ViiV Healthcare, H2 2012 195
Biopartners Holdings AG, H2 2012 196
Therapure Biopharma Inc., H2 2012 197
Vaxine Pty Ltd, H2 2012 198
VectorLogics, Inc., H2 2012 199
iTherX Pharmaceuticals Inc., H2 2012 200
VLP Biotech, Inc., H2 2012 201
ImQuest Life Sciences, H2 2012 202
Assessment by Monotherapy Products, H2 2012 203
Assessment by Combination Products, H2 2012 204
Assessment by Stage and Route of Administration, H2 2012 206
Assessment by Stage and Molecule Type, H2 2012 209
Hepatitis Therapeutics Drug Profile Updates 290
Hepatitis Therapeutics Discontinued Products 318
Hepatitis Therapeutics Discontinued Products (Contd..1) 319
Hepatitis Therapeutics Discontinued Products (Contd..2) 320
Hepatitis Therapeutics Discontinued Products (Contd..3) 321
Hepatitis Therapeutics Discontinued Products (Contd..4) 322
Hepatitis Therapeutics Discontinued Products (Contd..5) 323
Hepatitis Therapeutics Discontinued Products (Contd..6) 324
Hepatitis Therapeutics Discontinued Products (Contd..7) 325
Hepatitis Therapeutics Dormant Products 326
Hepatitis Therapeutics Dormant Products (Contd..1) 327
Hepatitis Therapeutics Dormant Products (Contd..2) 328
Hepatitis Therapeutics Dormant Products (Contd..3) 329
Hepatitis Therapeutics Dormant Products (Contd..4) 330
Hepatitis Therapeutics Dormant Products (Contd..5) 331
Hepatitis Therapeutics Dormant Products (Contd..6) 332
Hepatitis Therapeutics Dormant Products (Contd..7) 333
Hepatitis Therapeutics Dormant Products (Contd..8) 334
Hepatitis Therapeutics Dormant Products (Contd..9) 335
Hepatitis Therapeutics Dormant Products (Contd..10) 336
Hepatitis Therapeutics Dormant Products (Contd..11) 337
Hepatitis Therapeutics Dormant Products (Contd..12) 338
Hepatitis Therapeutics Dormant Products (Contd..13) 339
Hepatitis Therapeutics Dormant Products (Contd..14) 340
Hepatitis Therapeutics Dormant Products (Contd..15) 341
Hepatitis Therapeutics Dormant Products (Contd..16) 342
Hepatitis Therapeutics Dormant Products (Contd..17) 343
Hepatitis Therapeutics Dormant Products (Contd..18) 344
Hepatitis Therapeutics Dormant Products (Contd..19) 345
Hepatitis Therapeutics Dormant Products (Contd..20) 346
Number of Products under Development for Hepatitis, H2 2012 19
Products under Development for Hepatitis - Comparative Analysis, H2 2012 20
Products under Development by Companies, H2 2012 21
Products under Investigation by Universities/Institutes, H2 2012 33
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 203
Assessment by Combination Products, H2 2012 204
Assessment by Route of Administration, H2 2012 205
Assessment by Stage and Route of Administration, H2 2012 206
Assessment by Molecule Type, H2 2012 207
Assessment by Stage and Molecule Type, H2 2012 208